AU2014372562B2 - A method of making adenovirus and corresponding plasmids - Google Patents

A method of making adenovirus and corresponding plasmids Download PDF

Info

Publication number
AU2014372562B2
AU2014372562B2 AU2014372562A AU2014372562A AU2014372562B2 AU 2014372562 B2 AU2014372562 B2 AU 2014372562B2 AU 2014372562 A AU2014372562 A AU 2014372562A AU 2014372562 A AU2014372562 A AU 2014372562A AU 2014372562 B2 AU2014372562 B2 AU 2014372562B2
Authority
AU
Australia
Prior art keywords
site
adenovirus
arm
gene
restriction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014372562A
Other languages
English (en)
Other versions
AU2014372562A1 (en
Inventor
Alice Claire Noel BROWN
Tamara NICOLSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akamis Bio Ltd
Original Assignee
Akamis Bio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2014/072919 external-priority patent/WO2015059303A1/en
Application filed by Akamis Bio Ltd filed Critical Akamis Bio Ltd
Publication of AU2014372562A1 publication Critical patent/AU2014372562A1/en
Application granted granted Critical
Publication of AU2014372562B2 publication Critical patent/AU2014372562B2/en
Assigned to Akamis Bio Limited reassignment Akamis Bio Limited Request to Amend Deed and Register Assignors: PSIOXUS THERAPEUTICS LIMITED
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2820/00—Vectors comprising a special origin of replication system
    • C12N2820/55—Vectors comprising a special origin of replication system from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2014372562A 2013-12-23 2014-12-23 A method of making adenovirus and corresponding plasmids Active AU2014372562B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1322851.5 2013-12-23
GBGB1322851.5A GB201322851D0 (en) 2013-12-23 2013-12-23 Method
PCT/EP2014/072919 WO2015059303A1 (en) 2013-10-25 2014-10-24 Oncolytic adenoviruses armed with heterologous genes
AUPCT/EP2014/072919 2014-10-24
PCT/EP2014/079162 WO2015097220A1 (en) 2013-12-23 2014-12-23 A method of making adenovirus and corresponding plasmids

Publications (2)

Publication Number Publication Date
AU2014372562A1 AU2014372562A1 (en) 2016-07-21
AU2014372562B2 true AU2014372562B2 (en) 2020-11-26

Family

ID=50114629

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014372562A Active AU2014372562B2 (en) 2013-12-23 2014-12-23 A method of making adenovirus and corresponding plasmids

Country Status (10)

Country Link
US (1) US10472648B2 (enExample)
JP (2) JP6804133B2 (enExample)
KR (1) KR20160102024A (enExample)
CN (1) CN106062199B (enExample)
AU (1) AU2014372562B2 (enExample)
CA (1) CA2934015A1 (enExample)
GB (1) GB201322851D0 (enExample)
IL (1) IL246235B (enExample)
SG (1) SG11201604801WA (enExample)
WO (1) WO2015097220A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102272932B1 (ko) 2013-10-25 2021-07-05 싸이오서스 테라퓨틱스 엘티디. 이종 유전자로 무장된 종양살상 아데노바이러스
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein
US11155622B2 (en) * 2015-12-17 2021-10-26 Psioxus Therapeutics Limited Virus encoding an anti-TCR-complex antibody or fragment
KR102491752B1 (ko) 2016-08-29 2023-01-26 싸이오서스 테라퓨틱스 엘티디. 이중특이성 T 세포 세포 관여자(BiTE)가 보강된 아데노바이러스
GB201713765D0 (en) * 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
US20200017862A1 (en) * 2017-03-07 2020-01-16 University Of North Carolina Charlotte Systems and methods for single-strand break signaling and repair in a cell-free system
KR102702230B1 (ko) 2017-05-26 2024-09-03 에피센트알엑스, 인코포레이티드 트랜스진을 보유하는 재조합 아데노바이러스
AU2018277294B2 (en) * 2017-06-01 2025-04-24 Akamis Bio Limited Oncolytic virus and method
SG11202003058UA (en) * 2017-10-16 2020-04-29 Glaxosmithkline Biologicals Sa Replication competent adenoviral vectors
CN108424932B (zh) * 2018-03-13 2021-01-05 北京多赢时代转化医学研究院 重组溶瘤腺病毒、用于制备该重组溶瘤腺病毒的重组溶瘤腺病毒载体及其构建方法和应用
GB201814141D0 (en) * 2018-08-30 2018-10-17 Univ Oxford Innovation Ltd Method and compositions for producing a virus
GB202102049D0 (en) 2021-02-13 2021-03-31 Psioxus Therapeutics Ltd Viruses
CN113186151A (zh) * 2021-03-03 2021-07-30 郑州大学 一种提高腺病毒产毒能力的单克隆细胞、细胞库及制备方法
CN116380755B (zh) * 2023-03-20 2023-11-21 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） CD127+PMN-MDSCs在诊断支气管肺发育不良中的应用及诊断试剂盒
AU2024277678A1 (en) 2023-05-25 2025-11-27 Dispatch Biotherapeutics, Inc. Synthetic cancer antigens as targets for treating cancers
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2026117753A1 (en) 2024-11-27 2026-06-04 Dispatch Biotherapeutics, Inc. Viral vectors for expression of synthetic cancer antigens and chemokine and related methods and uses
WO2026117756A2 (en) 2024-11-27 2026-06-04 Dispatch Biotherapeutics, Inc. Systems and methods for expression of synthetic cancer antigens and cytokine receptors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU767975B2 (en) 1998-09-11 2003-11-27 Genvec, Inc. Alternatively targeted adenovirus
FR2799472B1 (fr) * 1999-10-07 2004-07-16 Aventis Pharma Sa Preparation d'adenovirus recombinants et de banques adenovirales
EP1327688A1 (en) 2002-01-14 2003-07-16 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Adenoviruses with enhanced lytic potency
US20060147420A1 (en) 2004-03-10 2006-07-06 Juan Fueyo Oncolytic adenovirus armed with therapeutic genes
US20040213764A1 (en) 2003-03-28 2004-10-28 William Wold Adenovirus replication-competent vectors expressing trail
CN1221666C (zh) * 2003-09-02 2005-10-05 广东省人民医院 腺病毒穿梭质粒及其构建方法
WO2005107474A2 (en) 2004-04-30 2005-11-17 Introgen Therapeutics, Inc. Oncolytic adenovirus armed with therapeutic genes
ES2358204T3 (es) * 2004-05-26 2011-05-06 Bayer Schering Pharma Aktiengesellschaft Adenovirus quiméricos para uso en el tratamiento del cáncer.
US20060292682A1 (en) 2004-07-22 2006-12-28 Hawkins Lynda K Addition of transgenes into adenoviral vectors
EP1819823A2 (en) 2004-12-01 2007-08-22 Bayer Schering Pharma Aktiengesellschaft Generation of replication competent viruses for therapeutic use
US8765146B2 (en) 2005-08-31 2014-07-01 Genvec, Inc. Adenoviral vector-based malaria vaccines
JP5448840B2 (ja) 2006-12-22 2014-03-19 プシオクサス・セラピューティクス・リミテッド 腫瘍退縮アデノウイルスの作出およびその使用
AU2011292120B2 (en) * 2010-08-16 2015-07-30 Salk Institute For Biological Studies Adenoviral assembly method
RU2013118723A (ru) 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы, кодирующие моноклональные антитела против ctla-4
CN102586327B (zh) 2012-01-18 2013-09-11 陕西师范大学 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用
WO2014138314A1 (en) 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
CN114317461A (zh) 2013-11-22 2022-04-12 德那翠丝有限公司 表达免疫细胞刺激受体激动剂的腺病毒
DK3288573T3 (da) 2015-04-30 2020-03-16 Psioxus Therapeutics Ltd Onkolytisk adenovirus, der koder for et b7-protein

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI, 0, Derwent World Patents Index, vol. 2012, no. 67, Database accession no. 2012-L80326, & CN102586327 A 20120718 (UNIV SHANXI NORMAL) *
HOFFMANN DENNIS ET AL, "Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli", BMC BIOTECHNOLOGY, (2006-08-03), vol. 6 *
JOSEPHINE M. JANSSEN ET AL, "Development of an AdEasy-based system to produce first- and second-generation adenoviral vectors with tropism for CAR- or CD46-positive cells", THE JOURNAL OF GENE MEDICINE, (2013-01-01), vol. 15 *

Also Published As

Publication number Publication date
CA2934015A1 (en) 2015-07-02
US20160319304A1 (en) 2016-11-03
CN106062199B (zh) 2019-12-03
AU2014372562A1 (en) 2016-07-21
SG11201604801WA (en) 2016-07-28
CN106062199A (zh) 2016-10-26
IL246235A0 (en) 2016-07-31
US10472648B2 (en) 2019-11-12
JP7104994B2 (ja) 2022-07-22
KR20160102024A (ko) 2016-08-26
WO2015097220A1 (en) 2015-07-02
GB201322851D0 (en) 2014-02-12
JP2017501695A (ja) 2017-01-19
JP2021040651A (ja) 2021-03-18
IL246235B (en) 2020-02-27
JP6804133B2 (ja) 2020-12-23

Similar Documents

Publication Publication Date Title
KR20160102024A (ko) 아데노바이러스 및 상응하는 플라스미드의 제조 방법
US12599678B2 (en) Methods and compositions for genomic integration
AU2019377141B2 (en) Enhanced systems for cell-mediated oncolytic viral therapy
AU2018347421B2 (en) Transgenic selection methods and compositions
TWI918097B (zh) 經修飾之腺病毒
KR20210149060A (ko) Tn7-유사 트랜스포존을 사용한 rna-유도된 dna 통합
AU2017371944B2 (en) Adenovirus polynucleotides and polypeptides
KR20220004959A (ko) 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아
KR20210093862A (ko) 유전자 요법 벡터를 제작하기 위한 조성물 및 방법
KR20100109914A (ko) 유인원 아과 ｂ 아데노바이러스 ｓａｄｖ-28,27,-29,-32,-33, 및 -35 및 그것의 사용
CN111733174B (zh) 一种分离的核酸分子及其用途
CN108697746A (zh) 编码抗tcr复合体抗体或片段的病毒
KR20240037192A (ko) 게놈 통합을 위한 방법 및 조성물
AU2018351308B2 (en) Replication competent adenoviral vectors
KR20240029020A (ko) Dna 변형을 위한 crispr-트랜스포손 시스템
CN113260704B (zh) CYP4V2和RdCVF在制备药物中的用途
CN115160413B (zh) 一种新型冠状病毒疫苗
CN116323942A (zh) 用于基因组编辑的组合物及其使用方法
CN114657213A (zh) 一种猪急性腹泻综合征冠状病毒人工染色体重组载体及其构建方法和应用
CN117157109A (zh) 腺病毒基因疗法载体
KR20230031929A (ko) 고릴라 아데노바이러스 핵산 서열 및 아미노산 서열, 이들을 함유하는 벡터, 및 이의 용도
CN116323955A (zh) 通过crispr/cas介导的体内末端解析拯救重组腺病毒
JP2002153275A (ja) スプーマウイルスプラスミドおよびその利用
EP3087187A1 (en) A method of making adenovirus and corresponding plasmids

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: AKAMIS BIO LIMITED

Free format text: FORMER NAME(S): PSIOXUS THERAPEUTICS LIMITED